Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Biomarker / Assay14 Peer-Reviewed Briefings
eGFR, Albuminuria & Renal Function
Estimated glomerular filtration rate slope, UACR, and tubular injury biomarkers.
Equations are population tools; at the bedside, non-glomerular filtration rate determinants of both creatinine and cystatin C can mislead. Schultheiss et al. show that replacing Chronic Kidney Disease Epidemiology Collaboration with European Kidney Function Consortium cystatin C-based equations reclassifies women, but not men, into milder chronic kidney disease stages, while outcome prediction is unchanged.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
RASi-based therapy, addressed as a time-updated pooled treatment, provided similar benefit across APOL1 genotypes, driven by albuminuric participants. Among individuals with two APOL1 risk alleles, outcomes were similar regardless of baseline albuminuria.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
The observations by Shimada et al. highlight both the promise and limitations of transcutaneous glomerular filtration rate, particularly in conditions that affect distribution volume, underscoring the need for rigorous evaluation across diverse physiological and disease states. Accurate assessment of glomerular filtration rate is central to renal evaluation in clinical and preclinical settings.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
In heart transplant recipients, dapagliflozin, compared with placebo (inactive comparison treatment), improved the slope of the eGFR from 2 weeks to 12 months of treatment. Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
It defines the conditions under which China-originated programs can generate globally practice-changing evidence. This review links regulatory reform, disease-specific opportunity, target biology, therapeutic format, and evidence quality across a decade of solid tumor development.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Treatment with first-line pumitamig plus nab-paclitaxel showed encouraging antitumour activity in patients with advanced or metastatic triple-negative breast cancer and a safety profile consistent with the mode of actions of both agents. These findings warrant further clinical evaluation in global Phase 2 and 3 trials.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
These findings indicate that ontogenically distinct and spatially segregated macrophage populations cooperate during early cGN and support further investigation of the CCR2 axis as a therapeutic target for macrophage-mediated kidney injury in cGN. To explore this, we used single-cell RNA sequencing (scRNA-seq), reporter-based bone marrow chimeras, timed clodronate liposome treatment, and chemokine blockade to define the spatiotemporal dynamics and functional roles of macrophage populations in nephrotoxic serum nephritis (NTSN), a model of cGN. scRNA-seq of total kidney and CD45 + immune cells revealed that proliferating macrophages and infiltrating monocytes expanded sharply by day five and declined by day ten, indicating that local proliferation, in addition to monocyte recruitment, contributes substantially to early macrophage accumulation in NTSN.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
In this Phase 2 nonrandomized clinical trial, HB0025 plus chemotherapy showed promising antitumor activity and manageable safety in patients with advanced, driver variant-negative NSCLC in both nonsquamous and squamous histologic types, supporting further evaluation in randomized Phase 3 clinical trials. This open-label, multicenter, Phase 2 nonrandomized clinical trial enrolled patients with stage IIIB/C or IV NSCLC without sensitizing EGFR, ALK, or ROS1 alterations across 13 hospitals in China.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Our clinically applicable cell therapy approach has the potential to control lupus nephritis by specifically dampening deleterious autoimmune responses. To investigate the efficacy (real-world effectiveness in the trial) of MIC therapy in lupus nephritis, splenocytes from syngeneic NZB/W F1 (BWF1) donor mice were incubated with mitomycin C, and then into BWF1 recipients at 25 weeks of age.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
These analyses provide individualized estimates of the expected treatment effect for any combination of medical therapies in HFrEF and HFmrEF/HFpEF on BP, kidney function and serum potassium. For HFrEF, the estimated treatment effects of ARNI + SGLT2i + sMRA on eGFR and serum potassium were -6.8 (-7.9, -5.4) ml min -1 m -2 and +0.30 (0.25, 0.35) mmol l -1 , respectively.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
As well, two bispecific ADCs, respectively targeting EGFR-c-MET and EGFR-B7-H3, appear active against multiple solid tumor types. The antibody-drug conjugate field is increasingly looking to go after more than one target at a time.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Long-term treatment with iptacopan led to sustained slowing in eGFR decline and proteinuria reduction that were also observed after switching from placebo (inactive comparison treatment). No new safety signals were observed.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In this safety assessment, SAEs were reported less frequently with semaglutide than placebo (inactive comparison treatment), with corresponding patterns observed for treatment discontinuations and AESIs. No unexpected safety concerns were identified across the spectrum of eGFR represented in the FLOW trial.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These findings indicate that EGFR-targeted D2C7-ATC therapy prolongs survival in a subset of patients with IDHwt rGBM via intratumoral and systemic immune activation. . Eight patients died on trial; all deaths were unrelated to D2C7-ATC.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
1 min read·Nature Medicine·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”